Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May 4;42(6):193.
doi: 10.1007/s12032-025-02752-y.

Exosomal miRNA-based theranostics in cervical cancer: bridging diagnostics and therapy

Affiliations
Review

Exosomal miRNA-based theranostics in cervical cancer: bridging diagnostics and therapy

Neha R Raghani et al. Med Oncol. .

Abstract

Cervical cancer (CC) remains a significant global health burden, particularly in low- and middle-income countries, where access to effective screening and treatment is limited. Despite advancements in conventional therapies, such as surgery, chemotherapy, and radiotherapy, challenges related to late-stage diagnosis, treatment resistance, and disease recurrence persist. The emergence of microRNAs (miRNAs) as key regulators of gene expression has revolutionized cancer diagnostics and therapeutics. Exosomal miRNAs, in particular, have garnered attention due to their stability, detectability in bodily fluids, and pivotal roles in tumor progression, metastasis, and immune modulation. This review provides a comprehensive overview of the role of exosomal miRNAs in the theranostic landscape of CC. We explore their involvement in disease pathogenesis, highlighting their potential as minimally invasive diagnostic biomarkers for early detection and disease monitoring. Furthermore, we examine their utility in therapeutic strategies, including miRNA-mediated drug delivery systems and miRNA-targeted interventions to overcome chemoresistance. Integrating exosomal miRNA profiling with current diagnostic modalities could enhance screening sensitivity and specificity, while miRNA-based therapies offer novel avenues to improve treatment efficacy. This review discusses recent advancements in miRNA research, current challenges in clinical translation, and future perspectives on leveraging exosomal miRNAs for personalized CC care.

Keywords: Biomarkers; Cervical cancer; Exosomal miRNA; Personalized medicine; Targeted therapy; Theranostics; miRNA therapeutics.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The authors declare no conflict of interest to report. Ethical approval: Not applicable.

Similar articles

References

    1. Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri: 2021 update. Int J Gynecol Obstet. 2021;155(S1):28–44. https://doi.org/10.1002/ijgo.13865 . - DOI
    1. Han L, Xu S, Zhou D, Chen R, Ding Y, Zhang M, et al. Unveiling the causal link between metabolic factors and ovarian cancer risk using Mendelian randomization analysis. Front Endocrinol. 2024;15:1401648. https://doi.org/10.3389/fendo.2024.1401648 . - DOI
    1. Wu N, Zhang X, Fang C, Zhu M, Wang Z, Jian L, et al. Progesterone enhances niraparib efficacy in ovarian cancer by promoting palmitoleic-acid-mediated ferroptosis. Research. 2024;7:0371. https://doi.org/10.34133/research.0371 . - DOI - PubMed - PMC
    1. Zhou J, Li H, Wu B, Zhu L, Huang Q, Guo Z, et al. Network pharmacology combined with experimental verification to explore the potential mechanism of naringenin in the treatment of cervical cancer. Sci Rep. 2024;14(1):1860. https://doi.org/10.1038/s41598-024-52413-9 . - DOI - PubMed - PMC
    1. Pang J, Ding N, Liu X, He X, Zhou W, Xie H, et al. Prognostic value of the baseline systemic immune-inflammation index in HER2-positive metastatic breast cancer: exploratory analysis of two prospective trials. Ann Surg Oncol. 2025;32(2):750–9. https://doi.org/10.1245/s10434-024-16454-8 . - DOI - PubMed

MeSH terms